WallStreetZenWallStreetZen

NASDAQ: QLGN
Qualigen Therapeutics Inc Stock Ownership - Who owns Qualigen Therapeutics?

Insider buying vs selling

Have Qualigen Therapeutics Inc insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when QLGN insiders and whales buy or sell their stock.

QLGN Shareholders

What type of owners hold Qualigen Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Noah Doyle150.30%7,787,131$3.12MInsider
Javelin Venture Partners LP136.03%7,047,804$2.83MInsider
Sekisui Diagnostics LLC38.22%1,980,233$794.07kInsider
Stonehenge Partners LLC15.77%817,272$327.73kInsider
Javelin Venture Partners I Spv I LLC6.23%322,753$129.42kInsider
Michael S. Poirier4.06%210,207$84.29kInsider
Matthew W. Foehr2.68%138,635$55.59kInsider
Ira E. Ritter1.59%82,352$33.02kInsider
Andrew J. Ritter1.59%82,352$33.02kInsider
Michael D. Step1.49%77,000$30.88kInsider

1 of 3

QLGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
QLGN0.87%99.13%
SLRX2.20%97.80%
INM13.28%11.17%Net BuyingNet Buying
APVO34.00%66.00%
SCNI0.03%0.05%

Qualigen Therapeutics Stock Ownership FAQ

Who owns Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ: QLGN) is owned by 3.18% institutional shareholders, 360.58% Qualigen Therapeutics insiders, and 0.00% retail investors. Noah Doyle is the largest individual Qualigen Therapeutics shareholder, owning 7.79M shares representing 150.30% of the company. Noah Doyle's Qualigen Therapeutics shares are currently valued at $3.11M.

If you're new to stock investing, here's how to buy Qualigen Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.